LncRNA H19: A Novel Biomarker in Cardiovascular Disease

Acta Cardiol Sin. 2024 Mar;40(2):172-181. doi: 10.6515/ACS.202403_40(2).20230925A.ABSTRACTCardiovascular disease is a major cause of death and disability worldwide. Recently, increasing evidence has demonstrated that long non-coding RNAs (lncRNAs) play critical roles in the pathogenesis of cardiovascular diseases, including atherosclerosis, coronary artery disease, dilated cardiomyopathy, diabetic cardiomyopathy, aortic dissection, and more. LncRNA H19 was the first to be described as a non-protein-coding mRNA-like molecule. A large number of studies have found that lncRNA H19 is related to the pathophysiological processes of cardiovascular diseases, and it is emerging as a potential key regulator of various heart diseases. In this review, we aim to summarize the role of lncRNA H19 in cardiovascular diseases in order to provide a theoretical basis for its potential use as a new therapeutic target in the future.PMID:38532821 | PMC:PMC10961637 | DOI:10.6515/ACS.202403_40(2).20230925A
Source: Atherosclerosis - Category: Cardiology Authors: Source Type: research